Leaner GSK ups R&D investments in immunology, genetics

GSK has formally started the process of splitting its innovative R&D and consumer health businesses into two companies, while continuing to cull down its clinical pipeline.

In its 4Q19 earnings Wednesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it had started a two-year separation process that would see its consumer healthcare JV hived off into a stand-alone company -- a continuation of plans it had already announced when it formed the JV with Pfizer Inc. in late 2018 (see “GSK, Pfizer JV Allows Both Pharmas to Focus on Innovation”)...